Diana Ernst, RPh, Author at Oncology Nurse Advisor

Diana Ernst, RPh

All articles by Diana Ernst, RPh

US Food and Drug Administration

Herceptin Hylecta Approved for the Treatment of HER2-Overexpressing Breast Cancer

The Food and Drug Administration (FDA) has approved Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) for the treatment of HER2-overexpressing breast cancer. Herceptin Hylecta is a combination of trastuzumab, an HER2/neu receptor antagonist, and hyaluronidase, an endoglycosidase used to increase the dispersion and absorption of coadministered drugs when administered subcutaneously. The product contains the same active ingredient…

Next post in Melanoma